JPMorgan maintained an Overweight rating on Bruker Corporation and raised its price target to $65 from $45. Analyst Casey Woodring updated the company model on June 8. The move follows Bruker's presentation of advances in its microbiology and infection diagnostics portfolio at ASM Microbe 2026, including FDA-approved updates to its MALDI Biotyper CA System that now identifies 549 clinically validated microbial species. The company also introduced research-use tools with libraries covering 5,325 species and is developing a rapid antimicrobial susceptibility testing workflow.
Bruker CorporationBruker presented advances in microbiology diagnostics at ASM Microbe 2026, including FDA-approved updates and new research tools.